Iconic Therapeutics
Industry: Ophthamology
Biopharma company licensing a novel recominant protein called hI-con1, which binds tissue factor, thus triggering cells that selectively destroy pathologic nerovascular blood vessels.
Company website: Iconic Therapeutics
